Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig T Vollert

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Scientific Reports|November 28, 2015
Formaldehyde scavengers function as novel antigen retrieval agentsCraig T Vollert, Wilna J Moree, Steven Gregory, et al.
Frontiers in Cellular Neuroscience|February 24, 2022
Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's DiseaseTasha R Womack, Craig T Vollert, Odochi Ohia-Nwoko, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Scientific Reports|November 28, 2015
Formaldehyde scavengers function as novel antigen retrieval agentsCraig T Vollert, Wilna J Moree, Steven Gregory, et al.
Frontiers in Cellular Neuroscience|February 24, 2022
Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's DiseaseTasha R Womack, Craig T Vollert, Odochi Ohia-Nwoko, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Pageof 1